Our R&D Pipeline

Phase 2 Ready Small Molecule: MCH-1 Antagonist CSTI-100 for Nonalcoholic Steatohepatitis (NASH) and Inflammatory Bowel Disease (IBD)

  • CSTI-100 is expected to be a multifactorial treatment for NASH by simultaneously reducing caloric intake, improving insulin sensitivity, and diminishing inflammatory and fibrotic pathways.
  • Literature and preliminary data shows IBD as another indication.
  • CSTI-100 is safe and well tolerated in Phase I clinical studies, t1/2 of 26 h.
  • Active areas of large licensing deals in recent years.
  • *We welcome academic researchers to contact us for the possibility of a collaboration to study CSTI-100. Click here for more information on CSTI-100.

    Orally Active Small Peptide for Type-2 Diabetes and Alzheimer’s Disease

  • First-in-Class: Novel leptin derived small peptides
  • Positive effects on glucose lowering, insulin sensitivity, weight and osteocalcin in preclinical models
  • Synergistic activity with insulin and GLP-1 compounds
  • Recent literature and data suggest a disease modifying effect on Alzheimer’s Disease (AD).
  • Novel targeting of the 5-HT3 Receptor to Treat Irritable Bowel Syndrome (IBS)

  • Irritable Bowel Syndrome (IBS) is a major functional disorder affecting 12% of adults with considerable economic burden (>$25 billion)
  • There is currently no effective treatment widely available
  • Projected market potential for safe and effective therapeutics is $15 billion
  • Novel targeting of 5-HT3 receptor delivering potential best-in-class treatment
  • Designed to avoid the side effects associated with maximal 5-HT3 receptor inhibition (i.e. severe constipation, ischemic colitis)
  • Excellent drug properties and safety profile
  • Competitive Glycine Transporter -1 (GlyT-1) Inhibitor CSTI-200 for CNS Diseases

  • Predicted wider therapeutic index: Competitive inhibitor of GlyT-1 with respect to glycine vs non-competitive GlyT-1 inhibitors that went into development
  • Evidence of clinically translational target engagement in rodents and monkeys with oral dosing
  • Evidence of significant improvements in a cognitive performance model in monkeys
  • Recent reports strongly suggest GlyT-1 inhibitors can relieve neuropathic pain and bone cancer pain
  • CSTI-200 is being developed for mild cognitive impairment (MCI) and/or chronic pain
  • Licensing Opportunity - Triple Reuptake Inhibitor BMS-866949

  • ConSynance is seeking to out-license the triple reuptake inhibitor (TRI) BMS-866949 on behalf of Albany Molecular Research, Inc. (AMRI)
  • The technology is the output of a collaboration between AMRI and Bristol-Myers Squibb
  • BMS-866949 is Phase II ready for multiple CNS disorders including depression
  • Three patent families with global protection
  • Please contact info@consynance.com for a non-confidential deck